title: Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.
abstract: Norbinaltorphimine (NorBNI), guanidinonaltrindole, and atrans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl) piperidine (JDTic) are selective kappa opioid receptor (KOR) antagonists having very long durations of action in vivo despite binding non-covalently in vitro and having only moderately high affinities. Consistent with this, we found that antagonist treatment significantly reduced the subsequent analgesic response of mice to the KOR agonist U50,488 in the tail-withdrawal assay for 14-21 days. Receptor protection assays were designed to distinguish between possible explanations for this anomalous effect, and we found that mice pretreated with the readily reversible opioid antagonists naloxone or buprenorphine before norBNI responded strongly in the tail-flick analgesia assay to a subsequent challenge with U50,488 1 week later. Protection by a rapidly cleared reagent indicates that norBNI did not persist at the site of action. In vitro binding of [(3)H]U69,593 to KOR showed that K(d) and Bmax values were not significantly affected by prior in vivo norBNI exposure, indicating that the agonist binding site was intact. Consistent with the concept that the long-lasting effects might be caused by a functional disruption of KOR signaling, both norBNI and JDTic were found to stimulate c-Jun N-terminal kinase (JNK) phosphorylation in HEK293 cells expressing KOR-GFP but not in untransfected cells. Similarly, norBNI increased phospho-JNK in both the striatum and spinal cord in wild type mice but not in KOR knock-out mice. Pretreatment of mice with the JNK inhibitor SP600125 before norBNI attenuated the long acting antagonism. Together, these results suggest that the long duration KOR antagonists disrupt KOR signaling by activating JNK.
authors: Department of Pharmacology, University of Washington, Seattle, Washington 98195, USA.
authors: Michael R
authors: MR
authors: Bruchas
authors: Tao
authors: T
authors: Yang
authors: Selena
authors: S
authors: Schreiber
authors: Mia
authors: M
authors: Defino
authors: Steven C
authors: SC
authors: Kwan
authors: Shuang
authors: S
authors: Li
authors: Charles
authors: C
authors: Chavkin
mesh_terms: D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / Q000494:pharmacology; D018712:Analgesics, Non-Narcotic / Q000494:pharmacology; D000818:Animals; D000873:Anthracenes / Q000494:pharmacology; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000378:metabolism*; D007700:Kinetics; D051379:Mice; D018345:Mice, Knockout; D008954:Models, Biological; D010766:Phosphorylation; D017473:Receptors, Opioid, kappa / Q000037:antagonists & inhibitors* / Q000737:chemistry*; D015398:Signal Transduction
chemical_list: D018712:Analgesics, Non-Narcotic; D000873:Anthracenes; D004791:Enzyme Inhibitors; D017473:Receptors, Opioid, kappa; C432165:pyrazolanthrone; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D048031:JNK Mitogen-Activated Protein Kinases
references: Nat Rev Mol Cell Biol. 2005 Aug;6(8):599-609
references: 16064136
references: Behav Pharmacol. 1995 Dec;6(8):815-820
references: 11224385
references: Eur J Pharmacol. 2000 May 12;396(1):49-52
references: 10822054
references: J Med Chem. 2004 Feb 12;47(4):1070-3
references: 14761209
references: Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13681-6
references: 11717429
references: Prog Clin Biol Res. 1990;328:65-8
references: 2154820
references: Trends Pharmacol Sci. 2001 Jul;22(7):368-76
references: 11431032
references: Pharmacol Rev. 1996 Dec;48(4):567-92
references: 8981566
references: J Pharmacol Exp Ther. 1997 Aug;282(2):676-84
references: 9262330
references: Biochem Biophys Res Commun. 1998 Feb 4;243(1):41-6
references: 9473476
references: Bioorg Med Chem Lett. 2007 Apr 15;17(8):2229-32
references: 17303418
references: J Pharmacol Exp Ther. 1999 Dec;291(3):1113-20
references: 10565831
references: J Neurochem. 2000 Feb;74(2):564-73
references: 10646507
references: Mol Pharmacol. 2006 Oct;70(4):1264-70
references: 16870886
references: J Biol Chem. 2006 Jun 30;281(26):18081-9
references: 16648139
references: J Biol Chem. 2004 Jan 16;279(3):1810-8
references: 14597630
references: J Pharmacol Exp Ther. 1982 Oct;223(1):157-62
references: 6288917
references: Life Sci. 1987 Mar 30;40(13):1287-92
references: 2882399
references: J Neurosci. 2006 Mar 29;26(13):3551-60
references: 16571763
references: J Pharmacol Exp Ther. 1993 Dec;267(3):1269-76
references: 8263790
references: Eur J Neurosci. 2002 Nov;16(9):1705-12
references: 12431223
references: Neurochem Res. 1996 Nov;21(11):1277-85
references: 8947917
references: Psychopharmacology (Berl). 2005 Nov;183(1):118-26
references: 16184376
references: Bioorg Med Chem Lett. 2005 Jun 2;15(11):2761-5
references: 15869877
references: J Med Chem. 2003 Jul 3;46(14):3127-37
references: 12825951
references: Psychopharmacology (Berl). 1994 Jul;115(3):311-9
references: 7871070
references: J Biol Chem. 2003 Sep 5;278(36):34631-40
references: 12815037
references: Nat Neurosci. 1999 Feb;2(2):151-6
references: 10195199
references: J Med Chem. 1987 Feb;30(2):238-9
references: 3027336
references: Eur J Pharmacol. 1992 May 14;215(2-3):345-8
references: 1327807
references: J Med Chem. 2001 Aug 16;44(17):2687-90
references: 11495579
references: J Biol Chem. 2005 Jul 29;280(30):27662-9
references: 15944153
references: J Pharmacol Exp Ther. 2007 Jan;320(1):1-13
references: 16803859
references: Biochim Biophys Acta. 2004 Mar 11;1697(1-2):89-101
references: 15023353
references: J Pharmacol Exp Ther. 1992 Mar;260(3):1237-43
references: 1312164
references: J Pharmacol Exp Ther. 1988 Jul;246(1):255-8
references: 2839664
references: Eur J Pharmacol. 2004 Oct 6;501(1-3):111-9
references: 15464069
references: J Pharmacol Exp Ther. 2004 Jul;310(1):301-10
references: 14996948
references: AAPS J. 2005 Oct 27;7(3):E704-22
references: 16353947
references: Science. 1982 Jan 22;215(4531):413-5
references: 6120570
references: J Neurosci. 2003 Jul 2;23(13):5674-83
references: 12843270
references: J Neurochem. 1998 Feb;70(2):635-45
references: 9453557
references: J Pharmacol Exp Ther. 1984 Apr;229(1):118-26
references: 6142942
references: J Med Chem. 2007 Jul 26;50(15):3596-603
references: 17580847
references: J Pharmacol Exp Ther. 2003 Apr;305(1):323-30
references: 12649385
references: Psychopharmacology (Berl). 2002 Oct;163(3-4):412-9
references: 12373442
references: Trends Pharmacol Sci. 2004 Apr;25(4):186-92
references: 15063082